Neuropeptide Y (NPY)

Neuropeptide Y (NPY)

Introduction

Neuropeptide Y (Npy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@dion2021]
<div class="infobox-header">Neuropeptide Y</div> [@decressac2012]
<div class="infobox-row"><strong>Gene:</strong> [NPY](/proteins/npy-protein)</div> [@malva2012]
<div class="infobox-row"><strong>UniProt ID:</strong> [P01303](https://www.uniprot.org/uniprot/P01303)</div> [@heilig2017]
<div class="infobox-row"><strong>PDB ID:</strong> [1RON](https://www.rcsb.org/structure/1RON)</div> [@sah2013]
<div class="infobox-row"><strong>Molecular Weight:</strong> ~4.3 kDa (36 amino acids)</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secreted, dense-core vesicles</div>
<div class="infobox-row"><strong>Protein Family:</strong> NPY family (NPY, PYY, PP)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Obesity, Anxiety, Depression</div>
</div>

Overview

Neuropeptide Y (NPY)

Introduction

Neuropeptide Y (Npy) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@dion2021]
<div class="infobox-header">Neuropeptide Y</div> [@decressac2012]
<div class="infobox-row"><strong>Gene:</strong> [NPY](/proteins/npy-protein)</div> [@malva2012]
<div class="infobox-row"><strong>UniProt ID:</strong> [P01303](https://www.uniprot.org/uniprot/P01303)</div> [@heilig2017]
<div class="infobox-row"><strong>PDB ID:</strong> [1RON](https://www.rcsb.org/structure/1RON)</div> [@sah2013]
<div class="infobox-row"><strong>Molecular Weight:</strong> ~4.3 kDa (36 amino acids)</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secreted, dense-core vesicles</div>
<div class="infobox-row"><strong>Protein Family:</strong> NPY family (NPY, PYY, PP)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Obesity, Anxiety, Depression</div>
</div>

Overview

Neuropeptide Y (NPY) is a 36-amino acid peptide belonging to the NPY family of peptides, which also includes peptide YY (PYY) and pancreatic polypeptide (PP)[@tatemoto1982]. Encoded by the NPY gene, this highly conserved peptide is one of the most abundant neuropeptides in the mammalian brain and acts as a powerful neuromodulator of stress responses, energy homeostasis, emotion, and synaptic plasticity. NPY exerts its effects through four G-protein coupled receptors (Y1, Y2, Y4, and Y5), making it a versatile signaling molecule with broad relevance to neurodegenerative disease research.

Structure

The NPY peptide adopts a characteristic PP-fold structure consisting of:

• An N-terminal polyproline helix (residues 1-8)
• A turn region (residues 9-17)
• An α-helical segment (residues 18-36)
• A C-terminal amide group essential for receptor binding

Key Structural Features

• Proline residues: Confer rigidity and unique conformation
• C-terminal tyrosine amide: Critical for receptor interaction
• Hydrophobic core: Mediates peptide self-association
• Receptor binding sites: Multiple regions interact with different receptors

Normal Function

Neuromodulation

• Inhibits glutamate release via Y2 receptor presynaptic inhibition
• Reduces GABAergic transmission
• Modulates dopamine release in striatum
• Alters [acetylcholine](/entities/acetylcholine) release in cortex

Energy Homeostasis

• Stimulates food intake through Y1 and Y5 receptors
• Reduces energy expenditure
• Regulates fat storage and metabolism
• Integrates hormonal signals (leptin, insulin)

Stress and Emotion

• Counteracts anxiety through Y2/Y5 receptors
• Modulates fear conditioning and extinction
• Influences depression-like behaviors
• Regulates HPA axis activity

Cognitive Functions

• Modulates hippocampal synaptic plasticity
• Influences memory consolidation
• Alters attention and executive function

Receptor Interactions

NPY signals through four G-protein coupled receptors with distinct pharmacology:

| Receptor | Primary Coupling | Brain Distribution | Key Functions |
|----------|-----------------|-------------------|---------------|
| Y1 (NPY1R) | Gi/o | [Cortex](/brain-regions/cortex), hippocampus, thalamus | Anxiety, feeding, memory |
| Y2 (NPY2R) | Gi/o | [Hippocampus](/brain-regions/hippocampus), hypothalamus | Presynaptic inhibition |
| Y4 (NPY4R) | Gi/o | Peripheral, limited CNS | Satiety |
| Y5 (NPY5R) | Gi/o | Hypothalamus, cortex | Feeding, seizures |

Disease Involvement

Alzheimer's Disease

• NPY levels altered in AD brains, particularly in regions affected by pathology
• Y2 receptor activation may provide neuroprotection against [Aβ](/proteins/amyloid-beta) toxicity
• NPY system offers potential therapeutic target for cognitive enhancement[@decressac2012]

Parkinson's Disease

• NPY co-localizes with dopaminergic [neurons](/entities/neurons) in substantia nigra
• Modulates motor function and non-motor symptoms
• Potential for neuroprotection in PD models

Obesity and Metabolic Disorders

• Central NPY drive contributes to hyperphagia
• Y1/Y5 receptor antagonists explored as anti-obesity agents
• Genetic variants associated with BMI

Anxiety and Depression

• NPY system dysregulation in stress-related disorders
• Lower NPY levels associated with PTSD vulnerability
• NPY agonists show anxiolytic potential

Therapeutic Targeting

Receptor-Selective Compounds

Strategies

• Stable peptide analogs with improved half-life
• Brain-penetrant receptor-selective compounds
• Gene therapy approaches
• Combination therapies

Research Directions

See Also

• [Proteins Index](/proteins)
• [NPY Gene](/proteins/npy-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)

External Links

• [UniProt: NPY](https://www.uniprot.org/uniprot/P01303)
• [PDB: NPY](https://www.rcsb.org/structure/1RON)
• [IUPHAR: NPY Receptors](https://www.guidetopharmacology.org/GRAC/ReceptorFamiliesForward?type=NPY)

Background

The study of Neuropeptide Y (Npy) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Molecular Mechanisms

Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the mammalian brain, exerting its effects through five Y receptor subtypes (Y1, Y2, Y3, Y4, Y5). Y1 and Y5 receptors are primarily responsible for the central effects of NPY on feeding, anxiety, and memory. These receptors couple to Gi/o proteins, inhibiting adenylate cyclase and reducing neuronal excitability through hyperpolarizing potassium currents.

NPY plays a crucial role in modulating synaptic transmission throughout the CNS. In the hippocampus, NPY inhibits glutamate release through presynaptic Y2 receptors, providing a neuroprotective mechanism against excitotoxicity. In the amygdala, NPY modulates anxiety-related behaviors through Y1 receptors in the basolateral complex.

Disease Associations

Alzheimer's Disease: NPY is significantly altered in Alzheimer's disease, with decreased levels in certain brain regions. The peptide may play a role in regulating amyloid-beta toxicity, and Y1 receptor signaling has been implicated in neuroprotection. Some studies suggest NPY could serve as a biomarker for cognitive decline.

Parkinson's Disease: NPY neurons are affected in Parkinson's disease, particularly in the basal ganglia. The peptide modulates dopaminergic signaling and may influence motor complications such as dyskinesias. NPY expression is also altered in the striatum following dopaminergic denervation.

Huntington's Disease: NPY interneurons are selectively vulnerable in Huntington's disease, contributing to the characteristic motor and cognitive deficits. The loss of NPY-expressing striatal interneurons may disrupt inhibitory circuits and contribute to disease progression.

Therapeutic Implications

NPY receptor agonists, particularly Y2 and Y5 receptor-selective compounds, are being investigated for neurodegenerative disease applications. Y2 agonists may provide neuroprotection by reducing excitotoxicity, while Y5 antagonists have shown promise in animal models of cognitive enhancement.

Research Directions

Current studies are exploring NPY as a potential therapeutic target, with focus on developing brain-penetrant Y receptor modulators that can cross the blood-brain barrier. Gene therapy approaches to increase NPY expression are also being investigated.

References